The DOI matches its Crossref record.
Polymers containing enzymatically degradable bonds, 7. Design of oligopeptide side‐chains in poly[N‐(2‐hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes
Abstract
N‐(2‐Hydroxypropyl)methacrylamide copolymers are considered to be a potential drug delivery system. To fulfil this role the drug‐polymer linkage must be susceptible to intralysosomal hydrolysis. Taking p‐nitroanilide as a drug analogue, copolymers were synthesized bearing oligopeptidyl‐p‐nitroanilide side‐chains designed to match known specificities of the lysosomal enzymes cathepsin L or cathepsin D. Degradation of side‐chains by rat liver lysosomal enzymes (measured by monitoring terminal p‐nitroaniline release) occurred only in the presence of reduced glutathione (5 mmol/l) and was effectively inhibited by leupeptin, indicating the involvement of thiol‐proteinases in every case. Depending on side‐chain composition, between 20 and more than 50% of the terminal p‐nitroaniline residues were liberated during a 5 h incubation. It has also been shown that 1) a polymer molecule may contain side‐chains of a single type that are nevertheless differentially susceptible to lysosomal hydrolysis; 2) two of the side‐chains studied liberate only a p‐nitroaniline residue, whereas the others also release amino‐acyl‐p‐nitroanilides; 3) the cleavage of all side‐chains displays a broad pH optimum pH 5 to pH 7; 4) the Michaelis‐Menten constant Km for side‐chain cleavage varied between 26,1 and 143,2 mg/ml, depending on the amino acid sequence of the side‐chain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
Self-citationPEGylation, successful approach to drug delivery
Veronese, F. M., & Pasut, G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03575-0 · Cited by 2,339
Polymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
Self-citationRecent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy
Pham, T. C., Nguyen, V.-N., Choi, Y., Lee, S., & Yoon, J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00381 · Cited by 1,813
Progress of drug-loaded polymeric micelles into clinical studies
Cabral, H., & Kataoka, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.042 · Cited by 837
The origins and evolution of “controlled” drug delivery systems
Hoffman, A. S. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.08.012 · Cited by 738
Polymer–drug conjugation, recent achievements and general strategies
Pasut, G., & Veronese, F. M. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.008 · Cited by 616
HPMA copolymers: Origins, early developments, present, and future☆
Kopeček, J., & Kopečková, P. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.10.004 · Cited by 576
Self-citationHPMA copolymer–anticancer drug conjugates: design, activity, and mechanism of action
Kopecek, J. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00075-8 · Cited by 562
Yuan, Y., Zhang, C., Gao, M., Zhang, R., Tang, B. Z., & Liu, B. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201408476 · Cited by 523
Prodrug Strategies in Anticancer Chemotherapy
Kratz, F., Müller, I. A., Ryppa, C., & Warnecke, A. (2008) · ChemMedChem · doi:10.1002/cmdc.200700159 · Cited by 486
Hydrogels as smart biomaterials
Kopeček, J., & Yang, J. (2007) · Polymer International · doi:10.1002/pi.2253 · Cited by 425
Self-citationShan, W., Zhu, X., Liu, M., Li, L., Zhong, J., Sun, W., Zhang, Z., & Huang, Y. (2015) · ACS Nano · doi:10.1021/acsnano.5b00028 · Cited by 395
Cheetham, A. G., Chakroun, R. W., Ma, W., & Cui, H. (2017) · Chem. Soc. Rev. · doi:10.1039/c7cs00521k · Cited by 367
Polymer–drug conjugates: Origins, progress to date and future directions
Kopeček, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.014 · Cited by 347
Self-citationTargeting angiogenesis with a conjugate of HPMA copolymer and TNP-470
Satchi-Fainaro, R., Puder, M., Davies, J. W., Tran, H. T., Sampson, D. A., Greene, A. K., Corfas, G., & Folkman, J. (2004) · Nature Medicine · doi:10.1038/nm1002 · Cited by 345
Polymer conjugates with anticancer activity
Putnam, D., & Kopeček, J. (1995) · Advances in Polymer Science · doi:10.1007/3540587888_14 · Cited by 315
Self-citationAdministration, distribution, metabolism and elimination of polymer therapeutics
Markovsky, E., Baabur-Cohen, H., Eldar-Boock, A., Omer, L., Tiram, G., Ferber, S., Ofek, P., Polyak, D., Scomparin, A., & Satchi-Fainaro, R. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.021 · Cited by 313
Intracellular targeting of polymer-bound drugs for cancer chemotherapy
NORI, A., & KOPECEK, J. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.10.006 · Cited by 303
Veronese, F. M., Schiavon, O., Pasut, G., Mendichi, R., Andersson, L., Tsirk, A., Ford, J., Wu, G., Kneller, S., Davies, J., et al. (2005) · Bioconjugate Chemistry · doi:10.1021/bc040241m · Cited by 282
Self-citationRejmanová, P., Kopeček, J., Pohl, J., Baudyš, M., & Kostka, V. (1983) · Die Makromolekulare Chemie · doi:10.1002/macp.1983.021841006 · Cited by 264
Self-citationDevelopment of HPMA copolymer–anticancer conjugates: Clinical experience and lessons learnt
Duncan, R. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.007 · Cited by 252
Self-citationDendrimeric micelles for controlled drug release and targeted delivery
Ambade, A. V., Savariar, E. N., & Thayumanavan, S. (2005) · Molecular Pharmaceutics · doi:10.1021/mp050020d · Cited by 245
Metadata
- Authors
- Duncan, R., Cable, H. C., Lloyd, J. B., Rejmanová, P., & Kopeček, J.
- Venue
- Die Makromolekulare Chemie
- Publisher
- Wiley
- Published
- 1983-10
- Volume
- 184
- Issue
- 10
- Pages
- 1997-2008
- ISSN
- 0025-116X (ISSN-L)
- OpenAlex
- W1830217992
- Cited by
- 193
- References
- 0
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.